Recombinant production of TGF- β3 protein and investigation of laser-based therapeutic applications

Wounds are one of the most undesirable conditions in living organisms. If the wound healing process develops or continues abnormally, scar tissue turns into hypertrophic tissue and then into keloid tissue. This situation is an undesirable process. Various chemical drugs, topical creams with protein content, sprays, tablets, biofilms, electric currents, radio waves, laser beams and ultrasound applications are used in order to accelerate wound healing and improve the patient's quality of life In this study, TGF-β3 + sfGFP fusion and diode laser application were investigated comparatively for wound healing. Recombinant TGF-β3 protein was produced with sfGFP as a fusion protein in E.coli then tested in human skin cells in cell culture with diode laser application. The protein, which was found to have no toxic effects, was also analysed in vivo. Wounds created in rats were treated with recombinant protein and diode laser application and then their healing processes were evaluated histologically. Histologically, It has been demonstrated histologically that recombinant TGF-β3 + sfGFP fusion and diode laser treatment applied to the wound together with this fusion complete the healing process better than the control groups and the improvement was indicated quantitatively. It has been revealed in this thesis that TGF-β3 + sfGFP fusion may be among the treatment options for diode laser-guided wound healing.